Italy suspends use of AstraZeneca vaccine for people under 60 year old

Italy on Friday suspended the use of the AstraZeneca vaccine for people under 60 years old, health officials announced at a weekly press conference on the Covid-19 pandemic

AstraZeneca, pharma, coronavirus, vaccine
IANS Rome
2 min read Last Updated : Jun 12 2021 | 7:11 AM IST

Italy on Friday suspended the use of the AstraZeneca vaccine for people under 60 years old, health officials announced at a weekly press conference on the Covid-19 pandemic.

The move came after an 18-year-old woman died of a blood clot Thursday after receiving an initial dose of AstraZeneca on May 25, Xinhua reported.

According to local media reports, the young woman suffered from autoimmune thrombocytopenia (meaning that she had a low blood platelet count) and was on double hormone therapy.

An investigation is underway to find out whether she had disclosed this information during the vaccine intake procedure, Italian news agency Ansa reported.

"The epidemiological scenario has changed, and so has the relationship between the benefits of vaccination and the potential risk of unusual blood clots," Franco Locatelli, coordinator of the Technical Scientific Committee (CTS) which gives advice to the government on how to handle the pandemic, said at the press conference.

The CTS recommends that people under 60 who received an initial dose of AstraZeneca be given a different vaccine for their second dose, Locatelli said, adding that this move represents "an excess of caution".

Over 40.7 million doses of vaccine have been administered in Italy and over 13.7 million people, or 25 percent of the population aged over 12, have been fully inoculated, according to the latest tally from the Ministry of Health on Friday.

--IANS

int/pgh

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Coronavirus VaccineItalyAstraZeneca

First Published: Jun 12 2021 | 7:11 AM IST

Next Story